5 Tips To Avoid Personal Finance Trouble When Buying A Home

Read More

Fed announces interest-rate decision

Read More

BlackRock Finds More Risk Assets at Insurers Than ’08

Read More

The Cambridge drugmaker saw its market value drop by about $1 billion in the first minutes of trading Monday, following a partial approval of a new depression drug late Friday. Cambridge-based Sage had applied to market the depression drug, zuranolone, as a treatment for both major depressive disorder (MDD) and postpartum depression (PPD). The U.S. Food and Drug Administration approved zuranolone, now marketed under the name Zurzuvae, for PPD but rejected it as a treatment for MDD, citing a lack of substantive data. The latter disorder would have presented a much larger market opportunity, analysts have noted. “We are devastated for patients and deeply disappointed with the FDA's position in issuing the [rejection],” Sage CEO Barry Greene said on a conference call Monday morning.

The proposed deal would result in the merger of Tabula Rasa and ExactCare Pharmacy, a portfolio company of Rhode Island-based Nautic Partners.

The new American Red Cross regional CEO of Arizona and New Mexico brings a wealth of experience in community efforts and nonprofit work.

The president of Kaiser Permanente Georgia uses her families' experiences as members of the health insurance plan to help guide her thinking about how her organization is performing.

Cincinnati Children’s will not proceed with plans to build a new specialized manufacturing facility in the region. The project, first announced in 2021 in conjunction with CTI, was expected to cost in excess of $100 million and add 150 jobs.

The new American Red Cross regional CEO of Arizona and New Mexico brings a wealth of experience in community efforts and nonprofit work.

Since helping EisnerAmper launch its Dallas presence in 2019, Jennifer Cuello has played a key role building up a book of business focused on venture capital funds, private equity funds, funds of funds and hedge funds.